headline | Euroskin

08:00 – 08:45	Registration
08:45 – 09:00	Welcome	President EUROSKIN / Cancer Foundation

Session I Introduction to biomarkers

09:00 – 09:45	Use of (epigenetic) Biomarkers	n.n.
09:45 – 10:30	Liquid biopsies	Babayan, A. (G)

10:30 – 11:00	Coffee break

Session II Different types of biomarkers in skin cancer

11:30 – 12:00	Risk-biomarkers	Hemminki, K. (G)
12:00 – 12:30	Diagnostic, predictive and progression biomarkers	n.n.
12:30 - 13:00	Therapy-(Resistance-) biomarkers	Neyns, B. (B)

13:00 – 14:00	Lunch

Session III Validation and Epidemiology

14:00 – 14:45	Validation of Biomarkers	West, C. (UK)
14:45 – 15:15	Use of Biomarkers in molecular epidemiology	Gandini, S. (I)

15:15 – 15:45	Coffee break

Session IV How to communicate results of Biomarker use

15:45 – 16:15	Differences between primary and secondary Prevention	n.n.
16:15 – 16:45	Ethical aspects of communication of (asked and) expected (bad?) medical results	Dupuis, J. (B)

16:45 – 17:30	Discussion

Session V Examples of biomarker use in skin cancer

09:00 – 09:30	Liquid biopsies vs Histology	n.n.
09:30 – 10:00	Circulating cf-DNA/cf-RNA	n.n.
10:00 – 10:30	Circulating tumor cells	A. Babayan (G)

10:30 – 11:00	Coffee break

11:00 – 11:30	Methylation analysis as biomarker	Page, C. (NO)
11:30 – 12:00	Circulating miRNA	Greinert, R. (G)
12:00 – 12:30	CirRNA and lncRNA	Leucci, E. (B)

12:30 – 13:00	Formulation of recommendations

13:00 – 14:00	Lunch

Revision of ECL Sun Safety Recommendations

13:30 – 13:45	Welcome & Introduction
13:45 – 14:15	What’s new? Update of the scientific evidence since 2007	Euroskin
14:15 – 14:45	Update of cancer leagues’ activities in sun & UV safety	ECL

14:45 – 15:15	Coffee break

15:15– 16:30	Presentation and discussion of proposed updated recommendations
16:30 – 16:45	Adoption of the updated recommendations
16:45 – 17:00	Concluding remarks

9th EUROSKIN workshop in Brussels, Belgium, 16-17 April, 2018